IDeAS Probiotic Pilot (IDeAS)

November 9, 2026 updated by: Stephanie A. Fritz, Washington University School of Medicine

Investigating Staphylococcus Aureus Colonization Dynamics in the Context of Bacillus Probiotic

Infections caused by Staphylococcus aureus pose a major public health threat, and existing prevention methods are burdensome to patients and provide only limited benefit. In this collaborative study, participants will trial a probiotic intervention and share their perspectives regarding study design and feasibility. The goal of this study is to characterize colonization kinetics of S. aureus and B. subtilis in the nares, skin, and stool before, during, and after administration of a nutritional supplement probiotic blend. We will establish the S. aureus intestinal colonization kinetics over a 3-month Natural History Phase, followed by a 1-month administration of the probiotic (Intervention Phase), and a 3-month Post-Intervention Observational Phase. Samples from the nares, skin, and stool will be collected at each of the 10 study visits to detect S. aureus and B. subtilis. We will also conduct interviews to assess acceptability, appropriateness, and feasibility of the probiotic and study regimen.

Study Overview

Detailed Description

The ongoing epidemic of Staphylococcus aureus skin and soft tissue infections in healthy individuals is a significant public health burden. S. aureus colonization (having the germ living in or on the body without symptoms) poses risk for developing symptomatic S. aureus infections. Thus, topical antimicrobials and antiseptics are often used to eliminate or reduce the burden of S. aureus from the nose and skin (known as decolonization). While current decolonization practices with topical antimicrobials effectively eliminate S. aureus carriage and prevent recurrent infections in the immediate period, their effectiveness wanes over time. While the nose has traditionally been considered the primary reservoir of S. aureus carriage, the intestine is also an important, yet under-appreciated, reservoir of S. aureus. Intestinal colonization can lead to persistent S. aureus colonization at other body sites despite topical antimicrobial decolonization.

Probiotics can promote a healthy gut microbiome by increasing the presence of beneficial bacteria and reducing the presence of pathogens, thereby improving digestive health and enhancing immune function. Bacillus subtilis is a benign microorganism that has been shown to inhibit S. aureus from colonizing the intestine. In a trial conducted in rural Thailand, daily oral administration of B. subtilis MB40 significantly reduced S. aureus in stool and nasal samples, without adverse effects. Bacillus coagulans has been demonstrated to decrease gastrointestinal symptoms, without adverse effects. B. subtilis and B. coagulans are both included as supplements in foods and available in pill form. In this investigation, we will study a probiotic blend of B. subtilis and B. coagulans, which is commercially available as a nutritional supplement, Ameo LifeTM Digest Probiotic. The goals of this study are to 1) establish the longitudinal colonization kinetics of S. aureus and B. subtilis before, during, and after probiotic administration; 2) assess the tolerability and delivery fidelity of the probiotic administration; and 3) engage participant perspectives to optimize study procedures and develop an intervention that is acceptable, appropriate, feasible, and likely to be adopted in real-world settings.

In this study, 20 healthy adults who are at risk for S. aureus infection who are colonized with S. aureus will be enrolled. S. aureus-colonized participants will be followed during a 3-month Natural History Phase, followed by a 1-month administration of the probiotic, and finally, a 3-month Post-Intervention Observational Phase. Stool, nasal, and skin samples will be collected 10 times over 7 months to quantify S. aureus and B. subtilis longitudinally. Participant acceptability and appropriateness will be assessed through brief, semi-structured interviews at the end of the probiotic administration and the conclusion of the Post-Intervention Observational Phase.

Study Type

Observational

Enrollment (Estimated)

20

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

  • Name: Stephanie Fritz, MD, MSCI
  • Phone Number: (314) 454-4114
  • Email: Fritz.s@wustl.edu

Study Contact Backup

  • Name: Mary Boyle, RN, MSN
  • Phone Number: 3(14) 286-1207
  • Email: mboyle@wustl.edu

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Participants meeting eligibility criteria who provide written informed consent. Participants will be recruited from a pre-existing participant pool developed through prior studies conducted by our research team. Participants will be from St. Louis, Missouri and surrounding areas.

Description

Inclusion Criteria

  1. Colonized with S. aureus in anterior nares, inguinal folds, or stool
  2. Age ≥ 18 years
  3. Able to complete the informed consent process
  4. Willing and able to complete the study protocol, study-related activities, and visits

Exclusion Criteria

  1. Pregnant or planning to become pregnant in the next 9 months
  2. Breastfeeding
  3. Abnormalities of the gastrointestinal tract (e.g., inflammatory bowel disease, ulcers, celiac diseases, etc.)
  4. Immunodeficiency
  5. Use of any antibiotics or probiotics outside of the study within 90 days of study screening
  6. Any contraindication to taking probiotics
  7. No permanent home, or living in a group home/ long term care facility

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: COHORT
  • Time Perspectives: PROSPECTIVE

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Characterize S. aureus in the stool from the pre-intervention sampling to the Week 4 sampling (completion of the Intervention Phase)
Time Frame: Start of the pre-intervention phase and end of the intervention phase

Compare change in S. aureus log10 S. aureus CFU/g count in stool from the pre-intervention sampling to the week-4 (end-of-dosing) sampling.

Start of the pre-intervention phase and end of the intervention phase
Evaluate the implementation outcomes of acceptability, appropriateness, and feasibility of the study procedures from the participant's perspective.
Time Frame: End of the intervention phase and end of the post-intervention phase

Create a participant-informed account of what makes the regimen acceptable and appropriate, benchmarked feasibility data against pre-specified go/no-go thresholds, and a prioritized set of protocol refinements. Comparing facilitators and barriers at the end-of-intervention visit versus the end-of-follow-up visit will indicate whether acceptability changes over time, and benchmarks falling below the thresholds will pinpoint where recruitment, retention, or scheduling procedures require modification.

End of the intervention phase and end of the post-intervention phase

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
S. aureus nares pre-intervention to week-4 (end-of-dosing) sampling.
Time Frame: Pre-intervention to week-4 sampling

Change in log10 S. aureus CFU/mL in the nares from the pre-intervention sampling to week-4 (end-of-dosing) sampling.

Pre-intervention to week-4 sampling
S. aureus nares pre-intervention to week-6 sampling.
Time Frame: Pre-intervention to week-6 sampling

Change in log10 S. aureus CFU/mL in the nares from the pre-intervention sampling to week-6 sampling.

Pre-intervention to week-6 sampling
S. aureus nares pre-intervention to month 2 sampling.
Time Frame: Pre-intervention sampling to month 2 sampling.

Change in log10 S. aureus CFU/mL in the nares from the pre-intervention sampling to month 2 sampling.

Pre-intervention sampling to month 2 sampling.
S. aureus nares pre-intervention to month 3 sampling.
Time Frame: Pre-intervention sampling to month 3 sampling.

Change in log10 S. aureus CFU/mL in the nares from the pre-intervention sampling to month 3 sampling.

Pre-intervention sampling to month 3 sampling.
S. aureus nares pre-intervention to month 4 sampling.
Time Frame: Pre-intervention to month 4 sampling.

Change in log10 S. aureus CFU/mL in the nares from the pre-intervention sampling to month 4 sampling.

Pre-intervention to month 4 sampling.
S. aureus inguinal fold pre-intervention to week-4 (end-of-dosing) sampling.
Time Frame: Pre-intervention to week-4 sampling

Change in log10 S. aureus CFU/mL in the inguinal fold from the pre-intervention sampling to week-4 (end-of-dosing) sampling.

Pre-intervention to week-4 sampling
S. aureus inguinal fold pre-intervention to week-6 sampling.
Time Frame: Pre-intervention to week-6 sampling

Change in log10 S. aureus CFU/mL in the inguinal fold from the pre-intervention sampling to week-6 sampling.

Pre-intervention to week-6 sampling
S. aureus inguinal fold pre-intervention to month 2 sampling.
Time Frame: Pre-intervention sampling to month 2 sampling.

Change in log10 S. aureus CFU/mL in the inguinal fold from the pre-intervention sampling to month 2 sampling.

Pre-intervention sampling to month 2 sampling.
S. aureus inguinal fold pre-intervention to month 3 sampling.
Time Frame: Pre-intervention sampling to month 3 sampling.

Change in log10 S. aureus CFU/mL in the inguinal fold from the pre-intervention sampling to month 3 sampling.

Pre-intervention sampling to month 3 sampling.
S. aureus inguinal fold pre-intervention to month 4 sampling.
Time Frame: Pre-intervention sampling to month 4 sampling.

Change in log10 S. aureus CFU/mL in the inguinal fold from the pre-intervention sampling to month 4 sampling.

Pre-intervention sampling to month 4 sampling.
Bacillus stool pre-intervention
Time Frame: Pre-intervention sampling

log10 B. subtilis CFU count at pre-intervention sampling

Pre-intervention sampling
Bacillus stool week-2 sampling
Time Frame: Week-2 sampling

log10 B. subtilis CFU count at week-2 sampling

Week-2 sampling
Bacillus stool week-4 sampling
Time Frame: Week-4 sampling

log10 B. subtilis CFU count at week-4 sampling

Week-4 sampling
Bacillus stool week-6 sampling
Time Frame: Week-6 sampling

log10 B. subtilis CFU count at week-6 sampling

Week-6 sampling
Bacillus stool month 2 sampling
Time Frame: Month 2 sampling

log10 B. subtilis CFU count at month 2 sampling

Month 2 sampling
Bacillus stool month 3 sampling
Time Frame: Month 3 sampling

log10 B. subtilis CFU count at month 3 sampling

Month 3 sampling
Bacillus stool month 4 sampling
Time Frame: Month 4 sampling

log10 B. subtilis CFU count at month 4 sampling

Month 4 sampling

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Stephanie A Fritz, MD, MSCI, Washington University School of Medicine

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

November 1, 2026

Primary Completion (Estimated)

November 1, 2030

Study Completion (Estimated)

November 1, 2031

Study Registration Dates

First Submitted

November 9, 2026

First Submitted That Met QC Criteria

November 9, 2026

First Posted (Actual)

November 16, 2026

Study Record Updates

Last Update Posted (Actual)

November 16, 2026

Last Update Submitted That Met QC Criteria

November 9, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe